NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Delcath Systems, Inc. (DCTH) Stock Analysis

Delcath Systems, Inc. (DCTH) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

DCTH

$16.48

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DCTH with… →

DCTH Key Statistics

As of Sep 4, 2026
Trading
Open
$16.32
Previous Close
$16.48
Day's Range
16.25–16.49
52-Week Range
8.12–17.42
Volume
180.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.57
Valuation
Market Cap
$571.84M
P/E Ratio
1648.00
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
366.22
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.60
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.99
EPS (ttm)Profit attributable to each share over the last twelve months.
0.01
Financials (FY)
Revenue (FY)
$85.23M+129.08%
Net Income (FY)
$2.70M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.56%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.70M
1-Year Return
+48.47%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
560.31K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DCTH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+63.17%
2025−16.11%
2024+189.42%
2023+15.56%
2022−53.55%
2021−56.75%
2020−15.67%
2019−89.16%
2018 (partial year)−79.26%

As of September 4, 2026.

DCTH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$85.23M$2.70M3.2%
2024$37.21M−$26.39M−70.9%
2023$2.07M−$47.68M−2308.9%
2022$2.72M−$36.51M−1342.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$85.23M$73.43M$660.00K$2.70M3.2%
2024$37.21M$31.02M−$12.41M−$26.39M−70.9%
2023$2.07M$1.43M−$38.18M−$47.68M−2308.9%
2022$2.72M$2.03M−$33.85M−$36.51M−1342.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DCTH Valuation vs Medical Devices Median

Median of 151 stocks
MetricDCTHMedical Devices medianvs median
P/E1648.0026.8061.5x the median
P/S ratio5.992.98101% above
Profit margin0.56%−1.69%2.2 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Delcath Systems, Inc. (DCTH) is capitalised at $571.84M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 156 employees.

DCTH last closed at $16.48 on September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $8.12 to $17.42. The latest close sits 102.96% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $85.23M. Against the prior fiscal year total of $37.21M, that is a change of +129.08%. The same year closed with net income of $2.70M. Profit margin runs at 0.56%. That is 2.2 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to 0.01.

Across the 4 fiscal years on file, revenue moves from $2.72M in 2022 to $85.23M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 1,648 times earnings. That is 61.5 times the Medical Devices median of 26.8. On forward earnings the ratio is 366.22. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.6. The price-to-sales ratio is 5.99. On price-to-sales that is 101.37% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The trailing one-year price return is +48.47%. Measured over 5 years, that is +10.80% a year compounded. The reported beta is 0.57. Daily returns over the trailing 8 years annualize to a volatility of 109.74%.

Growth & Income

No dividend is on file for DCTH.

So far in 2026 the price is +63.17%. Across the complete calendar years on file, 2024 returned +189.42% and 2019 returned −89.16%. Of the 7 complete calendar years on file, 2 finished higher.

Peer Comparison

Delcath Systems, Inc. (DCTH) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Delcath Systems, Inc. DCTH $571.84M 1648.0
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Delcath Systems, Inc. trades at a P/E of 1648.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Visit website →